Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) and its related conditions. With an estimated 1 billion people suffering from OSA around the world, it is the most predominant diseases, and can cause life-threatening high blood pressure, heart failure, stroke and other health problems. and life-threatening diseases. “We believe that Vivos’ sleep-specific AireO2 patient management technology represents a significant advancement in how medical and dental professionals will be able to treat sleep disorders,” Vivos’ chairman and CEO Kirk Huntsman in the press release. “Sleep apnea is a serious chronic disease that impacts much more than just sleep — it impacts patients’ quality of life and overall health. With AireO2, we believe that we can make it significantly easier for sleep disorder healthcare providers to manage their growing caseloads and increase the number of patients whom they can treat on any given day. We look forward to continuing the launch of AireO2 as a complement to our existing Billing Intelligence Service for our Vivos Integrated Practices and to actively pursuing AireO2 as a revenue source from other OSA-focused healthcare providers.”
To view the full press release, visit https://ibn.fm/9pnD1
About Vivos Therapeutics Inc.
Vivos Therapeutics Inc. is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective nonsurgical, noninvasive, nonpharmaceutical, and low-cost solution for patients with sleep disordered breathing (“SDB”), including mild-to-moderate obstructive sleep apnea (“OSA”). The company believes its products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (“CPAP”). For more information about the company, please visit www.VivosLife.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
